title: Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
abstract: BACKGROUND
  The effects of GH replacement therapy in patients who develop GH deficiency (GHD) after cure of acromegaly have not been established in a placebo-controlled study.
  
  
  OBJECTIVE
  The objective of the study was to determine whether GH replacement improves body composition, cardiovascular risk markers and quality of life in patients with GHD and prior acromegaly.
  
  
  METHODS
  This was a 6-month, randomized, placebo-controlled study.
  
  
  METHODS
  The study was conducted at a clinical translational science center.
  
  
  METHODS
  Participants included 30 subjects with prior acromegaly and current GHD.
  
  
  METHODS
  INTERVENTIONs included GH or placebo.
  
  
  METHODS
  Body composition (dual-energy x-ray absorptiometry and cross-sectional computed tomography at L4), cardiovascular risk markers (high-sensitivity C-reactive protein (hsCRP), total, high-density lipoprotein and low-density lipoprotein cholesterol, fibrinogen, and carotid intimal-medial thickness), and quality of life were measured.
  
  
  RESULTS
  The mean GH dose at 6 months was 0.58 +/- 0.26 mg/d. Total fat mass, visceral adipose tissue (-15.3 +/- 18.6 vs. 1.3 +/- 12.5%, P = 0.01), and total abdominal fat decreased, and fat-free mass increased, in the GH vs. placebo group. Mean hsCRP levels decreased, but there was no GH effect on other cardiovascular risk markers. There was no change in glycosylated hemoglobin or homeostasis model assessment insulin resistance index. Quality of life improved with GH. Side effects were minimal.
  
  
  CONCLUSIONS
  This is the first randomized, placebo-controlled study of the effects of GH replacement therapy on body composition and cardiovascular end points in patients who have developed GH deficiency after treatment for acromegaly, a disease complicated by metabolic and body composition alterations and increased cardiovascular risk. GH replacement decreased visceral adipose tissue, increased fat-free mass, decreased hsCRP, and improved quality of life in patients with GHD after cure of acromegaly, with minimal side effects and without an increase in insulin resistance.
authors.affiliation: Neuroendocrine Unit, Bulfinch 457B, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. kkmiller@partners.org
authors.forename: Karen K
authors.initials: KK
authors.lastname: Miller
authors.forename: Tamara
authors.initials: T
authors.lastname: Wexler
authors.forename: Pouneh
authors.initials: P
authors.lastname: Fazeli
authors.forename: Lindsay
authors.initials: L
authors.lastname: Gunnell
authors.forename: Gwenda J
authors.initials: GJ
authors.lastname: Graham
authors.forename: Catherine
authors.initials: C
authors.lastname: Beauregard
authors.forename: Linda
authors.initials: L
authors.lastname: Hemphill
authors.forename: Lisa
authors.initials: L
authors.lastname: Nachtigall
authors.forename: Jay
authors.initials: J
authors.lastname: Loeffler
authors.forename: Brooke
authors.initials: B
authors.lastname: Swearingen
authors.forename: Beverly M K
authors.initials: BM
authors.lastname: Biller
authors.forename: Anne
authors.initials: A
authors.lastname: Klibanski
mesh_terms: D000172:Acromegaly / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001823:Body Composition; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000009:adverse effects / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life
chemical_list: D019382:Human Growth Hormone; D002097:C-Reactive Protein